Sorry Dems, Affordability Is Trump's Strength
New Emails Reportedly Show Direct Biden White House Involvement in the Mar-a-Lago Raid
The Reason Why Dems Are Torpedoing Their 2024 Autopsy Is Beyond Abused
Last Night's Presser on the Brown University Shooter Took Many Wild Turns
How You Know the Lib Media Realizes There's Nothing in the Epstein Files...
The View Co-Host Drops Embarrassingly Shameful Take on Trump's Bonuses to Our Troops
What Trump Did to the Kennedy Center Triggered a Level-Five Lib Meltdown
Retirement Accounts Come Roaring Back in 2025
Can the Dark Ages Return?
Chanukah Is Relevant for Everyone – but Not in the Way You Might...
We Have Reached the Emily Litella Moment on Climate Change
Another Jewish Massacre on a Jewish Holy Day Is a Wake-Up Call to...
Virginia’s Incoming Democratic Governor Doubles Down on Bias
It Will Be Okay
Jon Ossoff Is Just Another Elitist Liberal
OPINION

Division In The Country, Division In The Market

The opinions expressed by columnists are their own and do not necessarily represent the views of Townhall.com.
AP Photo/Richard Drew, File

Thursday was one of those sessions that was perhaps overdue, but it mostly reinforced what we already knew.  In the process, it gave something to everyone.

Bears

Advertisement
  • The market dropped swiftly out of what should have been an innocuous Supreme Court decision.   
  • Market breadth remained negative throughout the session.
  • Would-be buyers remained on the sidelines, even when it looked as if major indices were turning around.

Bulls

  • All major equity indices closed off the lows of the session.
  • Some buyers showed up on weakness.
  • Selling came on light volume.

Deep Divide

Chasm: a marked division, separation, or difference

It feels as though every aspect of the nation is at a chasm from politics to wealth, so why not a massive division in the stock market between winners and losers?

Overall, the market is mostly marketing time, but it’s not standing still. Either stocks are up big or down big, and there is extraordinarily little middle ground. I cannot remember a time when winners were up this much, while losers were down this much.

S&P 500

  • 143 winners: +19.7%
  • The top 20: +58.8%
  • 362 losers: -25.0%
  • The bottom 20: -62.8%

I continue to wonder if the winners could somehow eventually offer coattails for the losers, but since June 10th, there were fewer winners (191 previously) and greater gains (14.5% previously).  

Dueling Headlines

Gyrations kicked up into the close from dueling headlines:

  • CALIFORNIA REPORTS 149 NEW VIRUS DEATHS, BIGGEST ONE-DAY JUMP, 3:40 PM
  • TRUMP SAYS ON TRACK TO LAUNCH VACCINE `VERY SOON,' 3:50 PM

We knew death counts associated with COVID-19 would rise on par with increased case counts. However, I’m watching how much they rise compared to spikes in cases over the prior two weeks. 

Advertisement

Message from the Bond Market

I continue to fret about the demand for treasuries, which continues to force yields to record low levels.  The yield curve isn’t suggesting a recession, but a demand for bonds, including 30-year maturities that sum up certain anxiety among investors.

Investors snapped up $19.0 billion for 30-year bonds. The 10-year were yielding 0.63% before the auction - after closing at 0.652% on Wednesday - and swooned to 0.605% at the close.

On Wednesday, investors bought $20.0 billion in 10-year bonds. I’m optimistic, and I know the nation will prevail, but I will pound the table when the 10-year is above 1.00%. Perhaps, that’s what sparks widespread equity buying.


Portfolio Approach

We took profits on a Healthcare position in our Hotline model portfolio to raise some cash.


Today’s Session

Gilead Sciences (GILD) announced that in clinical trials, Remdesivir can reduce the risk of mortality in Covid-19 patients by 62% versus those receiving standard care. The company stated this "an important finding that requires confirmation in prospective clinical trials."  The study also shows continued improvement in recovery times, for those patients taking the drug. GILD is up 2% on the news and the upbeat news has helped the broader market go positive.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement